Epinephrine (also called adrenaline) is given during cardiac arrest primarily to squeeze blood vessels throughout the body, forcing blood back toward the heart and brain when the heart has stopped pumping on its own. It’s the most commonly used drug in resuscitation, administered as a 1 mg dose every 3 to 5 minutes during CPR. Its role is straightforward in concept but complicated in practice: it reliably helps restart hearts, yet its benefits for long-term survival and brain recovery are far less clear-cut.
How It Works During Arrest
When your heart stops, blood pressure drops to nearly zero. Chest compressions alone generate some blood flow, but often not enough to push adequate blood through the coronary arteries (the vessels feeding the heart muscle itself). Without blood flow to the heart, it can’t restart. This is where epinephrine comes in.
Epinephrine activates two main types of receptors in the body. The first type causes blood vessels throughout the body to clamp down, which raises blood pressure and redirects whatever blood is circulating toward the heart and brain. This is the primary reason it’s used in cardiac arrest. The second type increases the heart rate and the force of heart contractions, which becomes relevant once the heart starts beating again.
The critical measurement during CPR is something called coronary perfusion pressure: essentially, how much blood is being pushed through the heart’s own blood supply. Research shows that this pressure needs to reach at least 15 mmHg for the heart to have any chance of restarting, and outcomes are significantly better when it reaches 35 to 40 mmHg. Epinephrine’s vessel-squeezing effect is what pushes this number high enough to make defibrillation or spontaneous restart possible. In animal studies, the animals whose hearts restarted showed roughly double the pressure response to epinephrine compared to those that didn’t survive.
When It’s Given and How
The timing depends on the type of cardiac arrest. Heart rhythms fall into two broad categories during arrest: shockable rhythms (where a defibrillator can potentially reset the heart) and non-shockable rhythms like asystole (flatline) and pulseless electrical activity, where the heart’s electrical system has either shut down or is firing without producing a pulse.
For non-shockable rhythms, guidelines recommend giving epinephrine as soon as possible, ideally within 3 to 5 minutes of the arrest. There’s no defibrillation option for these rhythms, so epinephrine and CPR are the primary tools. For shockable rhythms, the priority is defibrillation first, with epinephrine typically introduced after initial shocks have been attempted.
The standard adult dose is 1 mg delivered intravenously or through an intraosseous line (a needle placed directly into bone marrow when veins aren’t accessible). The drug is given in a dilute concentration, 1 mg in 10 mL of fluid, to allow precise dosing and rapid delivery. This dose is repeated every 3 to 5 minutes for as long as resuscitation continues.
The Survival Paradox
The largest and most rigorous study on epinephrine in cardiac arrest, known as the PARAMEDIC2 trial, enrolled over 8,000 patients with out-of-hospital cardiac arrest in the United Kingdom. The results, published in the New England Journal of Medicine, revealed a genuine tension at the heart of resuscitation medicine.
Patients who received epinephrine were more likely to be alive at 30 days: 3.2% survived compared to 2.4% who received a placebo. That’s a meaningful difference when applied across millions of cardiac arrests worldwide. However, when researchers looked at who survived with good brain function, the difference nearly vanished. About 2.2% of the epinephrine group and 1.9% of the placebo group survived with a favorable neurological outcome, a gap too small to be statistically significant.
In plain terms, epinephrine restarts more hearts, but a portion of those additional survivors end up with severe brain damage. This is one of the most debated findings in emergency medicine.
Why It Can Harm the Brain
The same vessel-squeezing action that makes epinephrine useful for the heart creates problems in the brain. Research using advanced imaging has shown that while epinephrine increases blood flow through larger brain vessels, it severely constricts the tiny microvessels (those smaller than 100 micrometers) that actually deliver oxygen to brain tissue. In one study, these microvessels shrank to just 57% of their normal diameter within 6 minutes of epinephrine administration, and this constriction lasted longer than the blood pressure boost it was intended to create.
This creates a deceptive picture. Surface-level monitoring might show increased blood flow to the brain, but deeper in the tissue, the smallest vessels are clamped down, reducing actual oxygen delivery where it matters most. The constriction persisted even after blood pressure returned to normal, meaning the brain’s oxygen supply remained compromised for longer than expected.
The Heart’s Own Oxygen Problem
Epinephrine creates a similar double-edged effect in the heart itself. While it increases blood flow to the coronary arteries, it simultaneously increases how much oxygen the heart muscle demands, even while the heart is in an abnormal rhythm and not pumping effectively. Research in animal models has shown that the heart’s lactate levels (a marker of oxygen starvation) increased significantly during CPR regardless of whether epinephrine was given, but tended to rise more in epinephrine-treated subjects.
This means epinephrine may not actually improve the balance between oxygen supply and demand in the heart during resuscitation, even when it successfully increases coronary blood flow. It’s delivering more blood to a heart that’s burning through oxygen faster because of the drug’s stimulating effects.
Why It’s Still Used
Despite these concerns, epinephrine remains the standard of care for a simple reason: nothing else works better. The increase in 30-day survival is real and reproducible. For non-shockable rhythms, which carry the worst prognosis and account for the majority of cardiac arrests, epinephrine and CPR are essentially the only interventions available. Some patients who receive epinephrine do survive with intact brain function, and without it, many of those individuals would have died.
The ongoing challenge is figuring out which patients benefit and which are harmed. Some people appear to be “hyporesponders,” meaning their blood vessels have lost so much tone by the time drugs arrive that epinephrine can’t generate enough pressure to restart the heart. Others respond robustly. Identifying these groups in real time, during the chaos of a resuscitation, remains one of the central problems in emergency medicine. For now, the 1 mg dose every 3 to 5 minutes continues as the global standard, a protocol that saves lives imperfectly while researchers work to refine who should receive it and when.